Roche's Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer - Seite 3

(95% CI), months 5.2
(4.4, 5.6) 4.3
(4.2, 4.5) HR (95% CI) 0.77 (0.62, 0.96)
p=0.017 1-year PFS rate 12.6% 5.4% CI, confidence interval; DOR, duration of response; HR, hazard ratio; ORR, objective response rate; PFS, progression-free survival

Safety for the Tecentriq and chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination. Grade 3-4 treatment-related adverse events (AEs) were reported in 56.6 percent of people receiving Tecentriq plus chemotherapy compared to 56.1 percent of people receiving chemotherapy alone.

About SCLC
Lung cancer is the leading cause of cancer death globally. ^[2] Each year 1.76 million people die as a result of the disease; this translates into more than 4,800 deaths worldwide every day. ^[2] Lung cancer can be broadly divided into two major types: non-small cell lung cancer (NSCLC) and SCLC, with SCLC accounting for approximately 15% of all lung cancer cases. ^[3] Survival rates for people with SCLC vary depending on the stage (extent) of the cancer at the time of diagnosis. ^[4] The five-year relative survival rate for people with stage I SCLC is approximately 31%; however, at stage IV, the five-year relative survival rate declines to approximately 2%.^[5]

About Tecentriq
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the activation of T cells. Tecentriq has the potential to be used as a foundational combination partner with cancer immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers.

Currently, Roche has eight Phase III lung cancer studies underway, evaluating Tecentriq alone or in combination with other medicines.

Tecentriq is already approved in the European Union, United States and more than 70 countries for people with previously treated metastatic NSCLC and for certain types of untreated or previously treated metastatic urothelial carcinoma (mUC).